AstraZeneca PLC
11978.00
22-August-25 08:29:58
15 minutes delayed
Stocks
-74.00
-0.61%
Today's range
11940.00 - 12126.00
ISIN
N/A
Source
Cboe
-
SOPHiA Genetics, AstraZeneca Team Up To Expand Liquid Biopsy Testing To 20 New Locations Globally
10 Sep 2024 08:30:45 By NASDAQ US Markets
-
AstraZeneca :Dato-DXd Fails To Significantly Improve Overall Survival In Phase III Lung Cancer Trial
09 Sep 2024 18:50:46 By NASDAQ US Markets
-
Chinese Authorities Detain AstraZeneca Employees
05 Sep 2024 14:39:29 By NASDAQ US Markets
-
NetDania - New 12 months High: AstraZeneca PLC
03 Sep 2024 00:15:42 By NetDania Notify
-
QIAGEN and AstraZeneca Expand Pact to Develop CDx in Chronic Diseases
30 Aug 2024 06:35:45 By NASDAQ Stocks
-
NetDania - New 12 months High: AstraZeneca PLC
30 Aug 2024 03:41:41 By NetDania Notify
-
Interesting AZN Put And Call Options For November 15th
23 Aug 2024 08:14:24 By NASDAQ Stocks
-
AZN: Enhertu Gets US Breakthrough Therapy Designation For HER2 Low/Ultralow Metastatic Breast Cancer
19 Aug 2024 00:08:28 By NASDAQ US Markets
-
AstraZeneca's Imfinzi Gets US Approval For Resectable Early-stage Lung Cancer
16 Aug 2024 00:28:46 By NASDAQ US Markets
-
AstraZeneca (AZN) Imfinzi Combo Gets EU Nod for Uterine Cancer
15 Aug 2024 04:38:12 By NASDAQ Stocks
-
Ex-Dividend Reminder: Cencora, AstraZeneca and Wells Fargo
07 Aug 2024 07:27:01 By NASDAQ Stocks
-
Here's What AstraZeneca's CEO Has to Say About the Weight Loss Drugs Market
04 Aug 2024 07:42:17 By NASDAQ US Markets
-
AstraZeneca: Calquence Combo Enhances PFS In First-Line CLL In Phase III Trial
29 Jul 2024 00:38:02 By NASDAQ US Markets
-
AstraZeneca Reports ODAC's Review Of Imfinzi - Quick Facts
26 Jul 2024 00:05:05 By NASDAQ US Markets
-
AstraZeneca Q2 Profit Rises, Lifts FY24 Outlook
24 Jul 2024 23:51:34 By NASDAQ US Markets
-
Interesting AZN Put And Call Options For August 23rd
03 Jul 2024 10:16:51 By NASDAQ US Markets
-
AstraZeneca: CHMP Recommends Lynparza And Imfinzi Combination For EU Approval In Endometrial Cancer
01 Jul 2024 00:09:21 By NASDAQ US Markets
-
Pharma Stock Roundup: FDA's CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN
28 Jun 2024 07:33:02 By NASDAQ Stocks
-
AstraZeneca: Imfinzi Trial Fails To Meet Endpoint In Early-stage Non-small Cell Lung Cancer
25 Jun 2024 00:08:02 By NASDAQ US Markets
-
AstraZeneca: Phase III Truqap Trial Plus Chemotherapy Fails To Meet Primary Goals In Breast Cancer
18 Jun 2024 00:15:21 By NASDAQ US Markets